Marker Therapeutics, Inc.

Monthly Archives: March 2015

TapImmune Appoints David Laskow-Pooley, CEO of London Pharma, to its Board of Directors

…SEATTLE, March 19, 2015 – TapImmune Inc. (OTCBB: TPIV) is pleased to announce the appointment of David Laskow-Pooley to the Company’s Board of Directors.

David brings 30 years of experience in all aspects of the discovery, development and commercialization of pharmaceutical and healthcare products. He has a successful track record of building, developing, operating and exiting start-up businesses, spin-outs from large corporations and business entities within large companies.

Read More

TapImmune Receives $1,000,000 from Strategic Investor

…Investment bolsters immediate capital needs for progressing clinical programs

SEATTLE, March 10, 2015 – TapImmune, Inc. (OTCQB: TPIV), is pleased to announce a US$1 million investment from Eastern Capital Limited under the same terms as the recent January 12, 2015 round of financing.

“We believe immunotherapy is one of the most exciting new approaches to the treatment of multiple cancers and promising early clinical results suggest TapImmune’s immunotherapies could become leading T-Cell stimulating therapeutics,” said Glynn Wilson Ph.D., CEO and Chairman of TapImmune.

Read More